Provider Remittance Advices
We are aware of provider remittance advices not populating into your portal. We are actively working on getting this resolved.
1 sep, 2021

Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer

Effective 1 de noviembre de 2021, for commercial products, criteria used for medical necessity review of the following tests can be found in this medical policy and will no longer be in the online authorization tool: Breast Cancer Index, Prosigna, MammaPrint and EndoPredict. Please refer to the draft medical policy for coding and other details here.

Powered by GlobalLink OneLink SoftwarePowered By OneLink